Takeda profits drop 20% on costs; AZ's development chief to retire

> Several of the keynote speakers for the upcoming BIO-Europe 2008 in Germany plan to focus on the ongoing revolution in drug discovery. R&D report

> The largest Japanese drugmaker, Takeda Pharmaceutical, reported Tuesday a 20 percent fall in second-quarter profit on acquisition costs and said a stronger yen had prompted it to trim its full-year forecast. Report

> John Patterson (photo), a key figure in the development of breast cancer drug tamoxifen, is to retire from AstraZeneca next March, the company said today; Patterson is now executive director in charge of development. AstraZeneca report

> Caraco Pharmaceuticals, a subsidiary of India's Sun Pharma, received a warning letter from the FDA over its manufacturing facility in Detroit. Report

> Minnesota has joined a growing number of states charging Eli Lilly with downplaying side effects of its antipsychotic Zyprexa and marketing the drug for unapproved uses. Report

> International pharmaceutical giant Merck Sharpe & Dohme is to hire 170 full-time staff for its new vaccine facility in county Carlow, Ireland. Report

> A Philadelphia judge has asked the state Superior Court to uphold another of his rulings dismissing a plaintiff's personal injury complaint that Wyeth, the manufacturer of her hormone replacement therapy drugs, is liable for her breast cancer. Report

> Strides Arcolab announced the company got the FDA nod for its Parnidronate Disodium injection 3mg/ml and 9mg/ml single use vials. Report

> A boost in revenue from a collaborative agreement with Merck helped Dynavax Technologies cut its loss in the third quarter. Report

> In a brief statement, Swedish biotech firm Q-Med said it has received a $502 million offer from from Ivytan, a firm owned by private equity group EQT V and Lyftet Holding. Report

> Yesterday the FDA announced several drug approvals. Report

> India's Bharat Biotech International and the state of Orissa have entered into a public-private partnership to construct a $20 million technology park for pharmaceutical and biotechnology companies. India report

And Finally... A none-too-subtle reminder of pharma's raison d'être: A new virus that causes fatal hemorrhagic fevers has been discovered in southern Africa. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.